Intent To Grant an Exclusive Field of Use License of a U.S. Government-Owned Patent Application, 54330 [2010-22175]

Download as PDF 54330 Federal Register / Vol. 75, No. 172 / Tuesday, September 7, 2010 / Notices BILLING CODE 5001–06–C DEPARTMENT OF DEFENSE Department of the Army wwoods2 on DSK1DXX6B1PROD with NOTICES_PART 1 Intent To Grant an Exclusive Field of Use License of a U.S. GovernmentOwned Patent Application Department of the Army, DoD. ACTION: Notice. AGENCY: In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive, revocable license for SUMMARY: VerDate Mar<15>2010 15:24 Sep 03, 2010 Jkt 220001 the field of use in the research reagent market to the invention described in U.S. Patent Application No. 61/252,675 entitled ‘‘Enhanced Substrates for The Protease Activity of Serotype A Botulinum Neurotoxin,’’ filed October 18, 2009, to List Biological Laboratories, with its principal place of business at 540 Division Street, Campbell, California 95008–6906. ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR–JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702– 5012. For licensing issues, Dr. Paul Mele, Office of FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 Research and Technology Applications (ORTA), (301) 619–6664. For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619–7808, both at telefax (301) 619–5034. Anyone wishing to object to the grant of this license can file written objections along with supporting evidence, if any, within 15 days from the date of this publication. Written objections are to be filed with the Command Judge Advocate (see ADDRESSES). SUPPLEMENTARY INFORMATION: Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2010–22175 Filed 9–3–10; 8:45 am] BILLING CODE 3710–08–P E:\FR\FM\07SEN1.SGM 07SEN1 EN07SE10.008</GPH> [FR Doc. 2010–22211 Filed 9–3–10; 8:45 am]

Agencies

[Federal Register Volume 75, Number 172 (Tuesday, September 7, 2010)]
[Notices]
[Page 54330]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-22175]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Intent To Grant an Exclusive Field of Use License of a U.S. 
Government-Owned Patent Application

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 35 U.S.C. 209(e), and 37 CFR 404.7 
(a)(1)(i), announcement is made of the intent to grant an exclusive, 
revocable license for the field of use in the research reagent market 
to the invention described in U.S. Patent Application No. 61/252,675 
entitled ``Enhanced Substrates for The Protease Activity of Serotype A 
Botulinum Neurotoxin,'' filed October 18, 2009, to List Biological 
Laboratories, with its principal place of business at 540 Division 
Street, Campbell, California 95008-6906.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele, 
Office of Research and Technology Applications (ORTA), (301) 619-6664. 
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-
7808, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: Anyone wishing to object to the grant of 
this license can file written objections along with supporting 
evidence, if any, within 15 days from the date of this publication. 
Written objections are to be filed with the Command Judge Advocate (see 
ADDRESSES).

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2010-22175 Filed 9-3-10; 8:45 am]
BILLING CODE 3710-08-P